MARKET WIRESeekingAlpha • 11h ago
PolyPid Ltd. (PYPD) Analyst/Investor Day - Slideshow2026-11-01. The following slide deck was published by PolyPid Ltd.
Why PYPD Stock dropped -3.29% Today — RQD Quant Desk Flash
$5.59 -3.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.55
PolyPid Ltd. (PYPD) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $113.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PYPD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PYPD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, PolyPid Ltd. (NASDAQ: PYPD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $5.59 (-3.29% 1D, market cap $113.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PYPD ranks #870 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PYPD compare to APYX and SKYA in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), PYPD carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APYX (Apyx Medical Corporation) holds a E grade (32/100 RQD, P/E N/A, ROIC -28.9%, cap $113.3M) and SKYA (SkyAI Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $126.7M). Among the 5-stock peer group, PYPD leads on earnings multiple (N/A) while APYX leads on capital efficiency (-28.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PYPD?
▼
Per PYPD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611842), PolyPid Ltd. generated $0 in revenue, -$34.2M in net income, and -$28.1M in free cash flow against $22.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.55 (-0.78%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-11.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PYPD)Realized 20D OHLCV Swing Band: ±11%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY PYPD SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)
FRED Regime × Technicals: 89% of 52W Range • RSI-14 at 54.7 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$5.07-6.9% Next Q
25
Q2 (-2Q)Grade E$4.72+11.2% Next Q
28
Q3 (-1Q)Grade E$5.25+6.5% Next Q
30
CurrentGrade E$5.59-8.9% Hist 90D α
33
Trajectory: E (25) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PYPD Turnaround Squeeze
While PYPD currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.19) and Max Pain ($5.87) forces dealer call-delta covering toward $6.13.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PYPD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PYPD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PYPD Stock dropped -3.29% Today — RQD Quant Desk Flash
PolyPid Ltd. (PYPD) dropped -3.29% to $5.59, trading at 89% of its 52-week range ($3.5 – $5.84). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 89% of its 52-week range ($3.5 – $5.84) with RSI-14 at 54.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11% around $5.59 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live PYPD Headlines & Catalysts
MARKET WIREBenzinga • 2d ago
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For FridayAnalysts initiated coverage with Buy/Overweight ratings on KZIA ($27), PSQL ($12), NSRX ($7) and LGCY ($16).
MARKET WIREBenzinga • 3d ago
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For ThursdayAnalysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.
MARKET WIREYahoo • 3d ago
PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026PETACH TIKVA, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment eff
MARKET WIREYahoo • 3d ago
PolyPid Targets 2027 D-PLEX100 Launch, Unveils Diabetic Foot Infection ProgramPolyPid (NASDAQ:PYPD) outlined plans to expand its commercial and development strategy through 2030 at an investor day, as the company approaches a November 28, 2026, FDA action date for its D-PLEX100 surgical-site infec
MARKET WIRESeekingAlpha • 3d ago
PolyPid Ltd. (PYPD) Analyst/Investor Day TranscriptPolyPid Ltd. (PYPD) Analyst/Investor Day October 28, 2026 11:30 AM EDTCompany ParticipantsDikla Akselbrad - CEO & DirectorOri Warshavsky - Chief...
MARKET WIREYahoo • 4d ago
PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot InfectionsCompany to host virtual Investor Day today at 11:30 AM ET, featuring key opinion leader Warren S. Joseph, DPM, FIDSA All scheduled FDA interactions on track and aligned with D-PLEX₁₀₀ November 28, 2026 PDUFA goal date Po
MARKET WIREBenzinga • 4d ago
This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayAnalysts initiated coverage: Hold ALHC; Overweight/$6 SPRO; Buy/$3 LABT; Buy/$6 CLOV.
MARKET WIREBenzinga • 5d ago
This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayAnalysts initiated Buy coverage on DRIO ($6), WATT ($15), PPL ($41), DNTH ($113); PYPD rated Outperform with a $10 target.
MARKET WIREBenzinga • 5d ago
Oppenheimer Initiates Coverage On PolyPid with Outperform Rating, Announces Price Target of $10Oppenheimer analyst Les Sulewski initiates coverage on PolyPid (NASDAQ:PYPD) with a Outperform rating and announces Price Target of $10.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PYPD)
- ✓Walkthrough of PYPD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PYPD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.22%▲ RESISTANCE BREAKOUT
2026-10-30O $5.54H $5.59L $5.38C $5.59VOL 101.3K
RES: $5.54SUP: $4.79SMA50: $5.19SMA200: $4.73
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PYPD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PYPD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PYPD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PYPD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PYPD)
Health Care Rank #870 of 1016
⚔️ APYX vs PYPD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PYPD vs. APYX, SKYA, LUNG, NYXH)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, PolyPid Ltd. (PYPD) ranks #870 by composite RQD confidence (33/100, grade E) and #643 by equity capitalization ($113.5M). Within this direct 5-issuer industry benchmark cohort, PYPD leads on earnings valuation at N/A trailing P/E, while APYX leads on capital efficiency and profitability with -28.9% ROIC and 62.5% gross margin. NYXH currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with PYPD at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PYPD
ACTIVE
PolyPid Ltd. | E | 33/100 | — | — | -35.0% | -3.29% | $113.5M | Benchmark Subject |
| APYX Apyx Medical Corporation | E | 32/100 | — | 62.5% | -28.9% | +3.07% | $113.3M | /apyx-vs-pypd → |
| SKYA SkyAI Inc. | D- | 36/100 | — | -30.0% | -35.0% | -0.68% | $126.7M | /skya-vs-pypd → |
| LUNG Pulmonx Corporation | D- | 38/100 | — | 74.2% | -35.0% | +25.60% | $135.9M | /lung-vs-pypd → |
| NYXH Nyxoah SA | C | 62/100 | — | — | — | -1.34% | $88.9M | /nyxh-vs-pypd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001611842In its most recent audited fiscal period (FY2025, filed 2025-12-31), PolyPid Ltd. (PYPD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$34.2M, operating cash flow of -$27.9M, and free cash flow of -$28.1M (-27.5% YoY). On the balance sheet, PYPD closed FY2025 with $22.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$34.2M | -$27.9M | -$28.1M | $22.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$29.0M | -$22.0M | -$22.0M | $25.2M | $634.0K |
| FY2023 (FY) | 2023-12-31 | $0 | -$23.9M | -$17.2M | -$17.2M | — | — |
3. PYPD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PYPD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, PolyPid Ltd. (NASDAQ: PYPD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $5.59 (-3.29% 1D, market cap $113.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PYPD ranks #870 in composite RQD confidence.
How does PYPD compare to APYX and SKYA in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), PYPD carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APYX (Apyx Medical Corporation) holds a E grade (32/100 RQD, P/E N/A, ROIC -28.9%, cap $113.3M) and SKYA (SkyAI Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $126.7M). Among the 5-stock peer group, PYPD leads on earnings multiple (N/A) while APYX leads on capital efficiency (-28.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PYPD?
Per PYPD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611842), PolyPid Ltd. generated $0 in revenue, -$34.2M in net income, and -$28.1M in free cash flow against $22.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PYPD trading relative to its 50-day, 200-day, and 52-week technical levels?
PYPD last traded at $5.59 (-3.29% on volume of 93,881 shares), positioning the stock +7.71% above its 50-day simple moving average ($5.19) and +18.18% above its 200-day simple moving average ($4.73). Across its 52-week range of $3.50 to $5.84, PYPD sits at the 89.3% percentile with a 14-day RSI of 54.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($4.98 to $6.20).
PYPD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PYPD stock moving today?
Why PYPD Stock dropped -3.29% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.